ArticleJournal of molecular histology2026
LncRNA expression signature correlated with cuproptosis: prognostic implications and insights into immune microenvironment in ovarian cancer.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer (OC) presents a formidable challenge in terms of early detection due to its subtle symptoms, often leading to diagnosis at advanced stages of the disease. Despite therapeutic advancements, survival rates exhibit limited improvement. This study delves into long non-coding RNAs (lncRNAs) associated with cuproptosis, aiming to anticipate the prognosis of OC and assess its immune status. The findings of this study provide a framework for enhancing the treatment of OC. RNA-seq and clinicopathological data of 379 TCGA-OC samples were retrieved from UCSC Xena. After extracting mRNAs/lncRNAs and screening CRLs via Pearson's analysis, a prognostic model was built and validated. Subgroup, PCA, GO/KEGG, immune infiltration, TMB, and drug sensitivity analyzes were conducted for evaluation. A prognostic ensemble, consisting of eight lncRNAs namely AC104820.2, EPB41L4A-AS1, LINC00996, RP11-110I1.6, RP11-367G6.3, RP11-443B7.3, RP11-4O1.2, and RP11-76E17.3, was effectively formulated. Independent prognostic factors for OC were identified through Cox analysis, with age and risk score emerging as noteworthy contributors. The prognostic signature demonstrated robust efficacy in the anticipation of 1-year, 3-year, and 5-year overall survival rates. Notably, individuals with low-risk OC manifested distinctive tumor immune microenvironments and exhibited an elevated tumor mutational burden. Furthermore, this low-risk cohort displayed heightened responsiveness to diverse therapeutic agents in comparison to their high-risk counterparts. Collectively, the comprehensive analysis of cuproptosis-associated lncRNAs serves a dual purpose in prognostication and elucidation of the immune microenvironment and therapeutic responsiveness in OC.
Indexed as
Identifiers
41739297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.